BioSpace News Archive

TFF Pharmaceuticals, Inc. today announced that it will release its financial results and business update for the first quarter of 2022 on Wednesday, May 11, 2022, after the close of the U.S. financial markets.

Aptinyx Inc. today presented data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28 – April 30, 2022 in New Orleans, Louisiana.

AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2022.

Amedisys, Inc. today announced that Chris Gerard, President and Chief Executive Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer, will present and conduct investor one on ones at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, at 5:40 p.m. ET.

Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the first quarter 2022 on Tuesday, May 10, 2022, before the market opens.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that its management will give an update on corporate progress at several international events in May.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open.

Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference held in Las Vegas, NV.

Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck KGaA, Darmstadt, Germany to grant them a sole license to evaluate Biocytogen’s proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date for therapeutic product development for all uses worldwide.

LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg and 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.